查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949588

抗菌藥物敏感性測試市場－全球產業規模、佔有率、趨勢、機會及預測（按產品、技術、應用、最終用戶、地區和競爭格局分類，2021-2031年）

Antimicrobial Susceptibility Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technique, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球抗生素敏感性測試市場預計將從 2025 年的 45.2 億美元成長到 2031 年的 61.3 億美元，複合年成長率為 5.21%。

此細分市場以研發和供應用於評估特定抗生素對致病微生物療效的診斷方法和儀器為特徵。推動該市場發展的主要因素是全球感染疾病負擔日益加重，以及為維持現有療法的有效性而強制推行抗生素舉措。此外，臨床上迫切需要快速診斷結果以促進患者康復並縮短住院時間，也進一步刺激了這項需求。

市場概覽
預測期 2027-2031
市場規模：2025年 45.2億美元
市場規模：2031年 61.3億美元
複合年成長率：2026-2031年 5.21%
成長最快的細分市場 藥物研發
最大的市場 北美洲

然而，市場成長面臨許多障礙，包括自動化藥敏試驗平台的高昂成本以及複雜的核准法規結構。這些財務和程序上的障礙往往會阻礙其推廣應用，尤其是在醫療資源匱乏的環境中。國際藥品製造商協會聯合會（IFPMA）在2025年強調了治療領域的不穩定性。該組織指出，2017年至2023年間，僅有10種新的抗生素或複方製劑獲得了嚴格的監管核准，並強調需要進行嚴格的測試才能有效控制抗藥性。

市場促進因素

全球抗菌藥物抗藥性（AMR）的日益嚴重是全球抗菌藥物敏感性檢測市場的主要促進因素，也因此需要精準的診斷設備來指導有效的治療。隨著細菌病原體不斷產生對標準藥物的抗藥性，依賴經驗處方變得風險重重，因此，在嚴重病例中，進行藥敏試驗對於避免治療失敗至關重要。抗藥性細菌的激增促使醫療系統越來越依賴先進的檢測基礎設施來改善藥物管理和患者預後。世界衛生組織（WHO）於2025年10月發布的《2025年全球抗生素抗藥性監測報告》指出，在2018年至2023年間，超過40%的受監測病原體-抗生素組合的抗藥性有所增加，凸顯了依賴準確藥敏資料的重要性。

同時，市場成長主要得益於自動化、高通量檢測系統的發展，這些系統滿足了檢查室對速度和營運效率的需求。現代微生物檢查室正迅速從勞動密集的手動技術轉向利用人工智慧的全自動系統，這些系統能夠提供更快、更標準化的結果，並在不增加人員的情況下實現大量檢體處理。這種向自動化的轉變體現在產業的強勁業績中。例如，生物梅里埃公司在2025年3月發布的「2024年財務表現」報告中指出，2024年微生物業務收入成長了8.3%，這主要得益於試劑銷售量的成長和自動化解決方案的廣泛應用。支持這些創新的生態系統也在日趨成熟，CARB-X的2025年報告就證明了這一點。該報告指出，其目標產品的三款產品（包括兩款新型診斷產品）已成功上市，證明了有效研發的成效。

市場挑戰

診斷產業面臨的重大經濟和監管障礙正直接限制全球抗菌藥物敏感性檢測市場的成長。製造商面臨日益複雜的核准流程，尤其是自動化系統的核准流程，而合規成本也呈指數級成長。這種監管負擔導致研發資金被抽調，並有效地阻礙了創新診斷設備的開發。因此，許多公司被迫推遲產品上市或完全退出某些地區市場，這限制了關鍵的敏感性檢測解決方案在醫療機構中的廣泛應用，而對抗抗藥性在這些機構中至關重要。

近期行業數據顯示，遵循成本之高昂印證了市場活動的下滑。據歐洲醫療技術協會（MedTech Europe）稱，到2025年，新監管標準下體外診斷產品的認證和維修成本將比先前的指令增加高達100%。該協會還指出，這些壁壘導致選擇歐盟作為其主要上市區域的主要製造商數量下降了40%。這些高准入門檻直接削弱了新型抗菌藥物敏感性檢測的商業性可行性，並阻礙了整體市場成長。

市場趨勢

無培養分子檢測技術的整合正在從根本上改變市場格局，它無需耗時的培養程序即可直接從臨床檢體中識別抗藥性基因。這種向基因型分析的轉變使臨床醫生能夠在數小時內而非數天內檢測到特定的抗藥性標記物，例如mecA和vanA，從而顯著加快膿毒症和複雜血流感染疾病的標靶治療。這些先進診斷技術的商業性成功已從近期的產業表現中得到印證。根據生物梅里埃公司於2025年3月發布的2024年財務業績報告，該公司包含快速血培養鑑定檢測的BIOFIRE非呼吸道病原體檢測組合在2024年的銷售額成長了17%，凸顯了臨床對快速分子檢測在嚴重感染疾病管理中日益成長的依賴性。

同時，照護現場（POC）解決方案的興起正在推動抗菌藥物敏感性檢測的去中心化，將關鍵分析從中心檢查室轉移到患者床邊。這一趨勢的驅動力源於急診和門診環境中對即時檢測結果的迫切需求，旨在減少不必要的院前抗生素處方，並促進合理用藥。這種去中心化基礎設施的覆蓋範圍正在迅速擴大，成熟的分子平台正利用其大規模的用戶基礎部署抗藥性檢測。例如，丹納赫公司在其2025年1月發布的「2024年第四季補充收益資訊」中報告稱，其Cefeed部門僅在第四季度就實現了約5.5億美元的呼吸系統業務收入，這表明快速診斷檢測擁有巨大的營運能力，足以支持其更廣泛地應用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球抗菌藥物敏感性檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（手動測試{MIC試紙、藥敏試驗紙片、藥敏試驗板}、自動化設備、耗材及培養基）
    • 依檢測方法（自動AST、Etest、稀釋法、紙錠擴散法等）
    • 依應用領域（藥物研發、藥敏試驗等）
    • 依最終用戶（醫院、診斷檢查室、生技/製藥公司、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美抗菌藥物敏感性檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲抗菌藥物敏感性檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區抗菌藥物敏感性檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲抗菌藥物敏感性檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美抗菌藥物敏感性檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球抗菌藥物敏感性檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bio-Rad Laboratories Inc.
  • Merck & Co., Inc.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • bioMerieux SA
  • Becton, Dickinson and Company
  • ELITech Group SAS
  • F. Hoffmann-La Roche Ltd.
  • Accelerate Diagnostics, Inc.
  • HiMedia Laboratories Private Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15570

The Global Antimicrobial Susceptibility Testing Market is projected to expand from USD 4.52 Billion in 2025 to USD 6.13 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 5.21%. This sector is characterized by the creation and supply of diagnostic methods and equipment designed to evaluate how effectively specific antimicrobial drugs work against pathogenic microorganisms. A key factor fueling this market is the rising global burden of infectious diseases, alongside the essential requirement for antimicrobial stewardship initiatives aimed at maintaining the effectiveness of current treatments. This demand is intensified by the urgent necessity for quick diagnostic results in clinical environments to enhance patient recovery and decrease the duration of hospitalizations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.52 Billion
Market Size 2031USD 6.13 Billion
CAGR 2026-20315.21%
Fastest Growing SegmentDrug Development
Largest MarketNorth America

However, market growth faces substantial obstacles due to the significant expenses linked to automated susceptibility testing platforms and the intricate regulatory frameworks required for their approval. These financial and procedural hurdles frequently restrict adoption, especially within healthcare settings facing resource limitations. The precarious nature of the therapeutic landscape was emphasized by the International Federation of Pharmaceutical Manufacturers and Associations in 2025, which noted that only 10 new antibiotics or combinations received approval from strict regulatory bodies between 2017 and 2023, highlighting the essential need for precise testing to effectively manage resistance patterns.

Market Driver

The increasing global incidence of antimicrobial resistance (AMR) serves as the main force driving the Global Antimicrobial Susceptibility Testing Market, creating a need for exact diagnostic instruments to direct successful treatment. As bacterial pathogens continue to develop defenses against standard medications, reliance on empirical prescribing has become risky, establishing a critical clinical need for susceptibility profiling to avert treatment failure in severe cases. This surge in resistance compels healthcare systems to depend heavily on sophisticated testing infrastructure to improve stewardship and patient results. In its 'Global Antibiotic Resistance Surveillance Report 2025' released in October 2025, the World Health Organization reported that antibiotic resistance increased in more than 40% of the monitored pathogen-antibiotic combinations between 2018 and 2023, emphasizing the vital reliance on accurate susceptibility data.

Concurrently, the market is receiving a significant boost from developments in automated and high-throughput testing systems that meet laboratory demands for speed and operational efficiency. Modern microbiology labs are quickly moving away from labor-intensive manual techniques toward fully automated systems that employ artificial intelligence to provide faster, standardized outcomes, thereby handling larger sample volumes without increasing staff. This transition to automation is reflected in strong industry performance; for instance, bioMerieux reported in its '2024 Financial Results' in March 2025 that its microbiology sales rose by 8.3% in 2024, largely fueled by higher reagent volumes and the uptake of automated solutions. The ecosystem supporting these innovations is also maturing, as evidenced by CARB-X in 2025, which noted that three supported products, including two new diagnostics, successfully entered the market, demonstrating effective R&D translation.

Market Challenge

The significant economic and regulatory hurdles present in the diagnostic industry are directly limiting the growth of the Global Antimicrobial Susceptibility Testing Market. As manufacturers encounter increasingly intricate approval processes, especially for automated systems, the funds needed for compliance have escalated drastically. This regulatory burden shifts capital away from research and development, effectively halting the creation of innovative diagnostic instruments. As a result, many firms are compelled to postpone product introductions or exit certain regional markets altogether, restricting the reach of critical susceptibility testing solutions in healthcare environments where they are most essential for fighting resistance.

Recent industry data regarding the severity of these compliance expenses confirms this reduction in market activity. According to MedTech Europe in 2025, the costs for certification and maintenance of in vitro diagnostics under new regulatory standards have risen by as much as 100% compared to earlier directives. Additionally, the association noted that the selection of the European Union as a primary launch region declined by 40% among major manufacturers because of these obstacles. Such high barriers to entry directly diminish the commercial feasibility of new antimicrobial susceptibility tests, thereby impeding the overall growth of the market.

Market Trends

The integration of culture-independent molecular testing techniques is fundamentally transforming the market by eliminating lengthy culture procedures to identify resistance genes directly from clinical samples. This move toward genotypic profiling enables clinicians to detect specific resistance markers, such as mecA or vanA, within hours instead of days, greatly speeding up targeted treatments for sepsis and complex bloodstream infections. The commercial success of these advanced diagnostics is clear in recent industry results; bioMerieux's '2024 Financial Results' from March 2025 show that sales of the company's BIOFIRE non-respiratory panels, which incorporate rapid blood culture identification assays, grew by 17% in 2024, emphasizing the increasing clinical dependence on rapid molecular testing for managing severe infections.

At the same time, the growth of point-of-care (POC) diagnostic solutions is decentralizing antimicrobial susceptibility testing, shifting critical analysis from central laboratories to the patient's bedside. This trend is fueled by the critical requirement for instant results in emergency and outpatient environments to reduce unnecessary antibiotic prescribing and enhance stewardship prior to hospital admission. The scope of this decentralized infrastructure is expanding rapidly, as established molecular platforms utilize their large installed bases to deploy resistance assays; for example, Danaher reported in its 'Supplemental Earnings Information for the Fourth Quarter 2024' in January 2025 that its Cepheid division achieved roughly $550 million in respiratory revenue during the fourth quarter alone, highlighting the substantial operational capacity available for the wider adoption of rapid diagnostic tests.

Key Market Players

  • Bio-Rad Laboratories Inc.
  • Merck & Co., Inc.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • bioMerieux SA
  • Becton, Dickinson and Company
  • ELITech Group SAS
  • F. Hoffmann-La Roche Ltd.
  • Accelerate Diagnostics, Inc.
  • HiMedia Laboratories Private Limited

Report Scope

In this report, the Global Antimicrobial Susceptibility Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antimicrobial Susceptibility Testing Market, By Product

  • Manual Tests {MIC Strips, Susceptibility Testing Disks, Susceptibility Plates}
  • Automated Instruments
  • Consumables & Media

Antimicrobial Susceptibility Testing Market, By Technique

  • Automated AST
  • Etest Method
  • Dilution
  • Disk Diffusion
  • Others

Antimicrobial Susceptibility Testing Market, By Application

  • Drug Development
  • Susceptibility Testing
  • Others

Antimicrobial Susceptibility Testing Market, By End User

  • Hospitals
  • Diagnostic Laboratories
  • Biotechnology & Pharmaceutical Companies
  • Others

Antimicrobial Susceptibility Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antimicrobial Susceptibility Testing Market.

Available Customizations:

Global Antimicrobial Susceptibility Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antimicrobial Susceptibility Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Manual Tests {MIC Strips, Susceptibility Testing Disks, Susceptibility Plates}, Automated Instruments, Consumables & Media)
    • 5.2.2. By Technique (Automated AST, Etest Method, Dilution, Disk Diffusion, Others)
    • 5.2.3. By Application (Drug Development, Susceptibility Testing, Others)
    • 5.2.4. By End User (Hospitals, Diagnostic Laboratories, Biotechnology & Pharmaceutical Companies, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Antimicrobial Susceptibility Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technique
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antimicrobial Susceptibility Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technique
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Antimicrobial Susceptibility Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technique
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Antimicrobial Susceptibility Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technique
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Antimicrobial Susceptibility Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technique
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antimicrobial Susceptibility Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technique
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Antimicrobial Susceptibility Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technique
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Antimicrobial Susceptibility Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technique
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Antimicrobial Susceptibility Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technique
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Antimicrobial Susceptibility Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technique
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia Pacific Antimicrobial Susceptibility Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technique
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Antimicrobial Susceptibility Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technique
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Antimicrobial Susceptibility Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technique
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Antimicrobial Susceptibility Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technique
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Antimicrobial Susceptibility Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technique
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Antimicrobial Susceptibility Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technique
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa Antimicrobial Susceptibility Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technique
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Antimicrobial Susceptibility Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technique
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Antimicrobial Susceptibility Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technique
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Antimicrobial Susceptibility Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technique
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. South America Antimicrobial Susceptibility Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technique
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Antimicrobial Susceptibility Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technique
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Antimicrobial Susceptibility Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technique
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Antimicrobial Susceptibility Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technique
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Antimicrobial Susceptibility Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bio-Rad Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. Thermo Fisher Scientific Inc.
  • 15.4. Danaher Corporation
  • 15.5. bioMerieux SA
  • 15.6. Becton, Dickinson and Company
  • 15.7. ELITech Group SAS
  • 15.8. F. Hoffmann-La Roche Ltd.
  • 15.9. Accelerate Diagnostics, Inc.
  • 15.10. HiMedia Laboratories Private Limited

16. Strategic Recommendations

17. About Us & Disclaimer